Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
July 22, 2024 08:03 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Alkeus Pharma Logo 2024.png
Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
July 18, 2024 10:20 ET | Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces presentation of a TEASE-3 study update showing progression stalled in early-stage Stargardt disease
Targretin Main Life
萬聯行在香港獲得Targretin®️(Bexarotene)用於皮膚T細胞淋巴瘤的上市批准
July 16, 2024 02:54 ET | MAIN LIFE CORPORATION LIMITED
香港和澳門的獲批為Targretin®️首次在中國區域內上市Bexarotene為國際臨床慣例用於治療復發性皮膚T細胞淋巴瘤(CTCL)的標準藥物 香港, July 16, 2024 (GLOBE NEWSWIRE) --...
Targretin Main Life
万联行获得Targretin®(Bexarotene 贝沙罗汀)在香港用于皮肤T细胞淋巴瘤的市场批准
July 16, 2024 02:54 ET | MAIN LIFE CORPORATION LIMITED
香港和澳门的批准标志着Targretin®首次在中国上市贝沙罗汀代表国际临床实践中对复发性皮肤T细胞淋巴瘤(CTCL)的标准治疗 香港, July 16, 2024 (GLOBE NEWSWIRE) -- 万联行有限公司(“Main Life”)今天宣布Targretin®(贝沙罗汀)胶囊在香港获得上市许可,用于治疗至少一次系统治疗无效的皮肤T细胞淋巴瘤 (Cutaneous T-cell...
Targretin Main Life
Main Life received Targretin® (Bexarotene) Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma
July 16, 2024 02:54 ET | MAIN LIFE CORPORATION LIMITED
Targretin® (Bexarotene) received Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma.
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
July 09, 2024 09:00 ET | Zevra Therapeutics
CELEBRATION, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and...
ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments
July 09, 2024 05:30 ET | ANEW MEDICAL, INC.
ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
June 27, 2024 08:00 ET | Quoin Pharmaceuticals, Inc.
Clinical site to be Opened in Saudi Arabia       Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has...
ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene
June 27, 2024 05:00 ET | ANEW MEDICAL, INC.
ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene
ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein
June 26, 2024 05:00 ET | ANEW MEDICAL, INC.
ANEW MEDICAL, INC. SECURES KEY PATENT IN EUROPE FOR HUMAN KLOTHO GENE RNA SLICE VARIANT AND PROTEIN